A Phase I Dose Escalation of ZD1839 (Iressa) (Days 1 and 2) and Docetaxel (Day 3) Every 3 Weeks in Patients With an Advanced Solid Tumor
Phase of Trial: Phase I
Latest Information Update: 16 Jan 2013
At a glance
- Drugs Gefitinib (Primary) ; Docetaxel
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Aug 2005 New trial record.